Business Standard

Lab stocks scramble for new growth in India as Covid gains halve

Surging healthcare spending and demand for Covid tests led to multifold share-price gains for pathology firms globally during the pandemic

Photo: Bloomberg
Premium

Photo: Bloomberg

Ashutosh Joshi | Bloomberg
India’s listed clinical laboratories are looking for new sources of growth to fuel investor interest after seeing their massive coronavirus-fueled stock rallies more than halved in recent months.
 
Surging healthcare spending and demand for Covid tests led to multifold share-price gains for pathology firms globally during the pandemic. Those gains have started to fade as outbreaks ease and countries look to reopen, while concerns over higher interest rates have sparked a flight from risky investments including biotech.

The tumble in Indian lab stocks has accelerated since the start of the year after disappointing results. The nation’s longest-listed pathology company

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Feb 21 2022 | 10:38 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com